Neointimal hyperplasia associated with synthetic hemodialysis grafts

Kidney International

Volumn 74, Issue 10, 2008, Pages 1247-1261

  Li, Li ^a   Terry, Christi M ^a   Shiu, Yan Ting E ^b   Cheung, Alfred K ^a,c,d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Utah   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Research 151N   (United States)

Author keywords

Arteriovenous graft; Blood flow; Hemodialysis; Hemodynamics; Imaging; Stenosis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR KINASE; DIPYRIDAMOLE; IMATINIB; NATRIURETIC PEPTIDE TYPE C; PACLITAXEL; RAPAMYCIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ARTERIOVENOUS FISTULA; ARTERY INTIMA PROLIFERATION; BIOCOMPATIBILITY; BRACHYTHERAPY; CELL THERAPY; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; GRAFT FAILURE; HEMODIALYSIS; HUMAN; INTRAVASCULAR ULTRASOUND; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SHEAR STRESS; STENOSIS; SURGICAL INJURY; T LYMPHOCYTE;

ANASTOMOSIS, SURGICAL; BLOOD VESSEL PROSTHESIS; CONSTRICTION, PATHOLOGIC; HUMANS; HYPERPLASIA; RENAL DIALYSIS; TUNICA INTIMA;

EID: 55249109152     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.318     Document Type: Review

References (225)

1. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62: 1109-1124.
2. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305-316.
3. Rayner HC, Besarab A, Brown WW et al. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44: 22-26.
4. Ravani P, Barrett B, Mandolfo S et al. Factors associated with unsuccessful utilization and early failure of the arterio-venous fistula for hemodialysis. J Nephrol 2005; 18: 188-196.
5. Saran R, Dykstra DM, Pisoni RL et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19: 2334-2340.
6. Lee H, Manns B, Taub K et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-622.
7. Schwab SJ, Oliver MJ, Suhocki P et al. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001; 59: 358-362.
8. United States Renal Data System. 2007 USRDS Annual Report 2007.
9. Asif A, Gadalean FN, Merrill D et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 2005; 67: 1986-1992.
10. Kelly BS, Heffelfinger SC, Whiting JF et al. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int 2002; 62: 2272-2280.
11. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17: 1112-1127.
12. Kanterman RY, Vesely TM, Pilgram TK et al. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995; 195: 135-139.
13. Roy-Chaudhury P, Kelly BS, Miller MA et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59: 2325-2334.
14. Swedberg SH, Brown BG, Sigley R et al. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80: 1726-1736.
15. Masaki T, Rathi R, Zentner G et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 2004; 66: 2061-2069.
16. Li L, Terry CM, Blumenthal DK et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007; 22: 3139-3146.
17. Rotmans JI, Velema E, Verhagen HJ et al. Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine, bilateral, carotid arteriovenous graft model. J Surg Res 2003; 113: 161-171.
18. Schwartz SM, deBlois D, O'Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-465.
19. Wilcox JN, Cipolla GD, Martin FH et al. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann N Y Acad Sci 1997; 811: 437-447.
20. Misra S, Doherty MG, Woodrum D et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int 2005; 68: 2890-2900.
21. Roy-Chaudhury P, Kelly BS, Melhem M et al. Novel therapies for hemodialysis vascular access dysfunction: fact or fiction!. Blood Purif 2005; 23: 29-35.
22. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84: 115-124.
23. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
24. Sarkar R, Meinberg EG, Stanley JC et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996; 78: 225-230.
25. Sarkar R, Webb RC. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J Vasc Res 1998; 35: 135-142.
26. McGeachie JK, Meagher S, Prendergast FJ. Vein-to-artery grafts: the long-term development of neo-intimal hyperplasia and its relationship to vasa vasorum and sympathetic innervation. Aus N Z J Surg 1989; 59: 59-65.
27. Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J Exp Med 1990; 172: 1749-1756.
28. Jovinge S, Hultgardh-Nilsson A, Regnstrom J et al. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol 1997; 17: 490-497.
29. Hansson GK, Holm J, Holm S et al. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991; 88: 10530-10534.
30. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432.
31. Duncan MR, Berman B. Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 1985; 162: 516-527.
32. Bobryshev YV, Inder SJ, Cherian SM et al. Colonisation of prosthetic grafts by immunocompetent cells in a sheep model. Cardiovasc Surg 2001; 9: 166-176.
33. Inder SJ, Bobryshev YV, Cherian SM et al. Identification of dendritic cells in ePTFE grafts explanted from humans. Cardiovasc Surg 2000; 8: 265-273.
34. Cherian SM, Bobryshev YV, Inder SJ et al. Involvement of dendritic cells in long-term aortocoronary saphenous vein bypass graft failure. Cardiovasc Surg 1999; 7: 508-518.
35. Cherian SM, Bobryshev YV, Inder SJ et al. Dendritic cells in venous pathologies. Angiology 1999; 50: 393-402.
36. Mattana J, Effiong C, Kapasi A et al. Leukocyte- polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-alpha secretion. Kidney Int 1997; 52: 1478-1485.
37. Miller KM, Anderson JM. Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers. J Biomed Mater Res 1988; 22: 713-731.
38. Dagtekin G, Schiffer R, Klein B et al. Modulation of angiogenic functions in human macrophages by biomaterials. Biomaterials 2003; 24: 3395-3401.
39. Haruguchi H, Teraoka S. Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: a review. J Artif Organs 2003; 6: 227-235.
40. Sivanesan S, How TV, Black RA et al. Flow patterns in the radiocephalic arteriovenous fistula: an in vitro study. J Biomech 1999; 32: 915-925.
41. Ballyk PD, Walsh C, Butany J et al. Compliance mismatch may promote graft-artery intimal hyperplasia by altering suture-line stresses. J Biomech 1998; 31: 229-237.
42. Hofer M, Rappitsch G, Perktold K et al. Numerical study of wall mechanics and fluid dynamics in end-to-side anastomoses and correlation to intimal hyperplasia. J Biomech 1996; 29: 1297-1308.
43. Fung YC. Biomechanics: Mechanical Properties of Living Tissues, 2nd edn, Springer-Verlag: New York, 1993.
44. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 1995; 9: 7-18.
45. Liu SQ. Biomechanical basis of vascular tissue engineering. Crit Rev Biomed Eng 1999; 27: 75-148.
46. Kakisis JD, Liapis CD, Sumpio BE. Effects of cyclic strain on vascular cells. Endothelium 2004; 11: 17-28.
47. Davies PF, Polacek DC, Shi C et al. The convergence of haemodynamics, genomics, and endothelial structure in studies of the focal origin of atherosclerosis. Biorheology 2002; 39: 299-306.
48. Shiu YT. Mechanical forces on cells. In: Bronzino JD (ed). The Biomedical Engineering Handbook: Tissue Engineering and Artificial Organs, 3rd edn, CRC Press Taylor & Francis Group, LLC: Boca Raton, 2006, pp 33.31-33.18.
49. Ene-Iordache B, Mosconi L, Remuzzi G et al. Computational fluid dynamics of a vascular access case for hemodialysis. J Biomech Eng 2001; 123: 284-292.
50. Krueger U, Zanow J, Scholz H. Comparison of two different arteriovenous anastomotic forms by numerical 3D simulation of blood flow. Int J Angiol 2000; 9: 226-231.
51. Krueger U, Zanow J, Scholz H. Computational fluid dynamics and vascular access. Artif Organs 2002; 26: 571-575.
52. Migliavacca F, Dubini G. Computational modeling of vascular anastomoses. Biomech Model Mechanobiol 2005; 3: 235-250.
53. Van Tricht I, De Wachter D, Tordoir J et al. Comparison of the hemodynamics in 6 and 4-7mm hemodialysis grafts by means of CFD. J Biomech 2006; 39: 226-236.
54. Loth F, Jones SA, Zarins CK et al. Relative contribution of wall shear stress and injury in experimental intimal thickening at PTFE end-to-side arterial anastomoses. J Biomech Eng 2002; 124: 44-51.
55. Caro CG, Fitz-Gerald JM, Schroter RC. Arterial wall shear and distribution of early atheroma in man. Nature 1969; 223: 1159-1160.
56. Kraiss LW, Geary RL, Mattsson EJ et al. Acute reductions in blood flow and shear stress induce platelet-derived growth factor-A expression in baboon prosthetic grafts. Circ Res 1996; 79: 45-53.
57. Mondy JS, Lindner V, Miyashiro JK et al. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997; 81: 320-327.
58. Sterpetti AV, Cucina A, D0Angelo LS et al. Response of arterial smooth muscle cells to laminar flow. J Cardiovasc Surg 1992; 33: 619-624.
59. Sterpetti AV, Cucina A, Santoro L et al. Modulation of arterial smooth muscle cell growth by haemodynamic forces. Eur J Vasc Surg 1992; 6: 16-20.
60. Ueba H, Kawakami M, Yaginuma T. Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor-beta 1 and tissue-type plasminogen activator. Arterioscler Thromb Vasc Biol 1997; 17: 1512-1516.
61. Song RH, Kocharyan HK, Fortunato JE et al. Increased flow and shear stress enhance in vivo transforming growth factor-beta1 after experimental arterial injury. Arterioscler Thromb Vasc Biol 2000; 20: 923-930.
62. Loth F, Fischer PF, Arslan N et al. Transitional flow at the venous anastomosis of an arteriovenous graft: potential activation of the ERK1/2 mechanotransduction pathway. J Biomech Eng 2003; 125: 49-61.
63. Liu SQ, Tieche C, Tang D et al. Pattern formation of vascular smooth muscle cells subject to nonuniform fluid shear stress: role of PDGF-beta receptor and Src. Am J Physiol Heart Circ Physiol 2003; 285: H1081-H1090.
64. Tarbell JM, Qui Y. Arterial wall mass transport: the possible role of blood phase resistance in the localization of arterial disease. In: Bronzino JD (ed). The Biomedical Engineering Handbook: Tissue Engineering and Artificial Organs. 3rd edn, CRC Press Taylor & Francis Group, LLC: Boca Raton, 2006, pp 9.1-9.15.
65. Lipowsky HH, Riedel D, Shi GS. In vivo mechanical properties of leukocytes during adhesion to venular endothelium. Biorheology 1991; 28: 53-64.
66. House SD, Lipowsky HH. In vivo determination of the force of leukocyte-endothelium adhesion in the mesenteric microvasculature of the cat. Circ Res 1988; 63: 658-668.
67. Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86: III74-III85.
68. Badimon JJ, Badimon L, Turitto VT et al. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb 1991; 11: 395-402.
69. Maalej N, Holden JE, Folts JD. Effect of shear stress on acute platelet thrombus formation in canine stenosed carotid arteries: an in vivo quantitative study. J Thromb Thrombolysis 1998; 5: 231-238.
70. Maalej N, Folts JD. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 1996; 93: 1201-1205.
71. Bassiouny HS, Song RH, Kocharyan H et al. Low flow enhances platelet activation after acute experimental arterial injury. J Vasc Surg 1998; 27: 910-918.
72. Sumpio BE, Banes AJ. Response of porcine aortic smooth muscle cells to cyclic tensional deformation in culture. J Surg Res 1988; 44: 696-701.
73. Mills I, Cohen CR, Kamal K et al. Strain activation of bovine aortic smooth muscle cell proliferation and alignment: study of strain dependency and the role of protein kinase A and C signaling pathways. J Cell Physiol 1997; 170: 228-234.
74. Li Q, Muragaki Y, Ueno H et al. Stretch-induced proliferation of cultured vascular smooth muscle cells and a possible involvement of local reninangiotensin system and platelet-derived growth factor (PDGF). Hypertens Res 1997; 20: 217-223.
75. Birukov KG, Shirinsky VP, Stepanova OV et al. Stretch affects phenotype and proliferation of vascular smooth muscle cells. Mol Cell Biochem 1995; 144: 131-139.
76. Mizutani T, Haga H, Kawabata K. Cellular stiffness response to external deformation: tensional homeostasis in a single fibroblast. Cell Motil Cytoskeleton 2004; 59: 242-248.
77. Maniotis AJ, Chen CS, Ingber DE. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proc Natl Acad Sci USA 1997; 94: 849-854.
78. Gladilin E, Micoulet A, Hosseini B et al. 3D finite element analysis of uniaxial cell stretching: from image to insight. Phys Biol 2007; 4: 104-113.
79. Ingber DE. Mechanobiology and diseases of mechanotransduction. Ann Med 2003; 35: 564-577.
80. Wilson E, Vives F, Collins T et al. Strain-responsive regions in the platelet-derived growth factor-A gene promoter. Hypertension 1998; 31: 170-175.
81. Ma YH, Ling S, Ives HE. Mechanical strain increases PDGF-B and PDGF beta receptor expression in vascular smooth muscle cells. Biochem Biophys Res Commun 1999; 265: 606-610.
82. Hu Y, Bock G, Wick G et al. Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress. FASEB J 1998; 12: 1135-1142.
83. Kawabe J, Okumura S, Lee MC et al. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286: H1845-H1852.
84. Hamada K, Takuwa N, Yokoyama K et al. Stretch activates Jun N-terminal kinase/stress-activated protein kinase in vascular smooth muscle cells through mechanisms involving autocrine ATP stimulation of purinoceptors. J Biol Chem 1998; 273: 6334-6340.
85. Reusch HP, Chan G, Ives HE et al. Activation of JNK/SAPK and ERK by mechanical strain in vascular smooth muscle cells depends on extracellular matrix composition. Biochem Biophys Res Commun 1997; 237: 239-244.
86. Zeidan A, Broman J, Hellstrand P et al. Cholesterol dependence of vascular ERK1/2 activation and growth in response to stretch: role of endothelin-1. Arterioscler Thromb Vasc Biol 2003; 23: 1528-1534.
87. Li W, Chen Q, Mills I et al. Involvement of S6 kinase and p38 mitogen activated protein kinase pathways in strain-induced alignment and proliferation of bovine aortic smooth muscle cells. J Cell Physiol 2003; 195: 202-209.
88. Darbeau MZ, Lutz RJ, Collins WE. Simulated lipoprotein transport in the wall of branched arteries. Asaio J 2000; 46: 669-678.
89. Li C, Hu Y, Mayr M et al. Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways. J Biol Chem 1999; 274: 25273-25280.
90. Kakisis JD, Pradhan S, Cordova A et al. The role of STAT-3 in the mediation of smooth muscle cell response to cyclic strain. Int J Biochem Cell Biol 2005; 37: 1396-1406.
91. Chen AH, Gortler DS, Kilaru S et al. Cyclic strain activates the pro-survival Akt protein kinase in bovine aortic smooth muscle cells. Surgery 2001; 130: 378-381.
92. Sedding DG, Seay U, Fink L et al. Mechanosensitive p27Kip1 regulation and cell cycle entry in vascular smooth muscle cells. Circulation 2003; 108: 616-622.
93. Mills I, Letsou G, Rabban J et al. Mechanosensitive adenylate cyclase activity in coronary vascular smooth muscle cells. Biochem Biophys Res Commun 1990; 171: 143-147.
94. Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am J Nephrol 1998; 18: 379-383.
95. Dumars MC, Thompson WE, Bluth EI et al. Management of suspected hemodialysis graft dysfunction: usefulness of diagnostic US. Radiology 2002; 222: 103-107.
96. Bacchini G, Cappello A, La Milia V et al. Color doppler ultrasonography imaging to guide transluminal angioplasty of venous stenosis. Kidney Int 2000; 58: 1810-1813.
97. Bakker CJ, Peeters JM, Bartels LW et al. Magnetic resonance techniques in hemodialysis access management. J Vasc Access 2003; 4: 125-139.
98. Zhang J, Hecht EM, Maldonado T et al. Time-resolved 3D MR angiography with parallel imaging for evaluation of hemodialysis fistulas and grafts: initial experience. AJR Am J Roentgenol 2006; 186: 1436-1442.
99. Planken RN, Tordoir JH, Dammers R et al. Stenosis detection in forearm hemodialysis arteriovenous fistulae by multiphase contrast-enhanced magnetic resonance angiography: preliminary experience. J Magn Reson Imaging 2003; 17: 54-64.
100. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-267.
101. Terry cM, Goodrich KC, Hadley JR et al. No contrast, in vivo magnetic resonance imaging (MRI) of hemodialysis vascular access hyperplasia. J Am Soc Nephrol 2006; 17: 557A.
102. Misra S, Woodrum DA, Homburger J et al. Assessment of wall shear stress changes in arteries and veins of arteriovenous polytetrafluoroethylene grafts using magnetic resonance imaging. Cardiovasc Intervent Radiol 2006; 29: 624-629.
103. Arbab-Zadeh A, Mehta RL, Ziegler TW et al. Hemodialysis access assessment with intravascular ultrasound. Am J Kidney Dis 2002; 39: 813-823.
104. Terry CM, Li L, Kuji T et al. Intravascular ultrasound for imaging stenosis in a pig model of hemodialysis grafts. J Am Soc Nephrol 2005; 16: 11A
105. McLennan G, Trerotola SO, Forney M et al. Short-term patency and safety of an expanded polytetrafluoroethylene encapsulated endoluminal device at the venous anastomosis of a canine arteriovenous graft model. J Vasc Interv Radiol 2001; 12: 227-234.
106. Johnson MS, McLennan G, Lalka SG et al. The porcine hemodialysis access model. J Vasc Interv Radiol 2001; 12: 969-977.
107. Kostamaa H, Donovan J, Kasaoka S et al. Calcified plaque cross-sectional area in human arteries: correlation between intravascular ultrasound and undecalcified histology. Am Heart J 1999; 137: 482-488.
108. Weichert F, Wawro M, Muller H et al. Registration of biplane angiography and intravascular ultrasound for 3D vessel reconstruction. Methods Inf Med 2004; 43: 398-402.
109. Ye C, Mao Z, Rong S et al. Multislice computed tomographic angiography in evaluating dysfunction of the vascular access in hemodialysis patients. Nephron 2006; 104: c94-c100.
110. Ko SF, Huang CC, Ng SH et al. MDCT angiography for evaluation of the complete vascular tree of hemodialysis fistulas. AJR Am J Roentgenol 2005; 185: 1268-1274.
111. Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42: 1390-1397.
112. Jacobson GM, Dourron HM, Liu J et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res 2003; 92: 637-643.
113. Chang CJ, Ko PJ, Hsu LA et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43: 74-84.
114. Ram SJ, Work J, Caldito GC et al. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 2003; 64: 272-280.
115. Dember LM, Holmberg EF, Kaufman JS. Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 2004; 66: 390-398.
116. Moist LM, Churchill DN, House AA et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14: 2645-2653.
117. Robbin ML, Oser RF, Lee JY et al. Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes. Kidney Int 2006; 69: 730-735.
118. Clark TW. Nitinol stents in hemodialysis access. J Vasc Interv Radiol 2004; 15: 1037-1040.
119. Vesely TM, Amin MZ, Pilgram T. Use of stents and stent grafts to salvage angioplasty failures in patients with hemodialysis grafts. Semin Dial 2008; 21: 100-104.
120. Rotmans JI, Pattynama PM, Verhagen HJ et al. Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: a 4-week follow-up study. Circulation 2005; 111: 1537-1542.
121. Pasquinelli G, Freyrie A, Preda P et al. Healing of prosthetic arterial grafts. Scanning Microsc 1990; 4: 351-362.
122. Schmedlen RH, Elbjeirami WM, Gobin AS et al. Tissue engineered vascualr grafts. In: Bronzino JD (ed). The Biomedical Engineering Handbook: Tissue Engineering and Artificial Organs. 3rd edn, CRC Press Taylor & Francis Group, LLC: Boca Raton, 2006, pp 55.51-55.13.
123. Didisheim P, Watson JT. Cadiovascular applications. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE (eds). Biomaterials Science: An Introduction to Materials in Medicine. Academic Press: San Diego, 1996, 283-297.
124. Zhang Z, Wang Z, Liu S et al. Pore size, tissue ingrowth, and endothelialization of small-diameter microporous polyurethane vascular prostheses. Biomaterials 2004; 25: 177-187.
125. Voskerician G, Rodriguez A, Gingras PH. Macroporous condensed poly(tetra fluoro-ethylene). II. In vivo effect on adhesion formation and tissue integration. J Biomed Mater Res A 2007; 82: 426-435.
126. Legeais JM, Drubaix I, Briat B et al. Influence of ePTFE polymer implant permeability on the rate and density of corneal extracellular matrix synthesis. J Biomed Mater Res 1997; 36: 49-54.
127. Jorgensen CS, Paaske WP. Physical and mechanical properties of ePTFE stretch vascular grafts determined by time-resolved scanning acoustic microscopy. Eur J Vasc Endovasc Surg 1998; 15: 416-422.
128. Nakao A, Miyazaki M, Oka Y et al. Creation and use of a composite polyurethane-expanded polytetrafluoroethylene graft for hemodialysis access. Acta Med Okayama 2000; 54: 91-94.
129. Guidoin R, Domurado D, Couture J et al. Chemically processed bovine heterografts of the second generation as arterial substitutes: a comparative evaluation of three commercial prostheses. J Cardiovasc Surg 1989; 30: 202-209.
130. Pare G, Guidoin R, Marois M et al. (Evaluation of two commercial bovine vascular heterografts (author's transl)). J Chir 1980; 117: 331-339.
131. Winsett OE, Wolma FJ. Complications of vascular access for hemodialysis. South Med J 1985; 78: 513-517.
132. Hurt AV, Batello-Cruz M, Skipper BJ et al. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. Am J Surg 1983; 146: 844-847.
133. Brems J, Castaneda M, Garvin PJ. A five-year experience with the bovine heterograft for vascular access. Arch Surg 1986; 121: 941-944.
134. Salmon P. Vascular access for hemodialysis using bovine heterografts and polytetrafluoroethylene conduits. Can J Surg 1981; 24: 59-63.
135. Oakes DD, Spees EK, Light JA et al. A three year experience using modified bovine arterial heterografts for vascular access in patients requiring hemodialysis. Ann Surg 1978; 187: 423-429.
136. Wellington JL. Expanded polytetrafluoroethylene prosthetic grafts for blood access in patients on dialysis. Can J Surg 1978; 21: 420-422.
137. Haimov M, Burrows L, Schanzer H et al. Experience with arterial substitutes in the construction of vascular access for hemodialysis. J Cardiovasc Surg 1980; 21: 149-154.
138. Doyle DL, Fry PD. Polytetrafluoroethylene and bovine grafts for vascular access in patients on long-term hemodialysis. Can J Surg 1982; 25: 379-382.
139. Butler HGr, Baker LDJ, Johnson JM. Vascular access for chronic hemodialysis: polytetrafluoroethylene (PTFE) versus bovine heterograft. Am J Surg 1977; 134: 791-793.
140. Elliott MP, Gazzaniga AB, Thomas JM et al. Use of expanded polytetrafluoroethylene grafts for vascular access in hemodialysis: laboratory and clinical evaluation. Am Surg 1977; 43: 455-459.
141. Pasternak BM, Paruk S, Kogan S et al. A synthetic vascular conduit (expanded PTFE) for hemodialysis access-a preliminary report. Vasc Surg 1977; 11: 99-102.
142. Baker LDJ, Johnson JM, Goldfarb D. Expanded polytetrafluoroethylene (PTFE) subcutaneous arteriovenous conduit: an improved vascular access for chronic hemodialysis. Trans Am Soc Artif Intern Organs 1976; 22: 382-387.
143. Harder F, Landmann J. Trends in access surgery for hemodialysis. Surg Annu 1984; 16: 135-149.
144. Zincke H. Critical review of the use of carotid bovine grafts for hemodialysis. Eur Surg Res 1976; 8: 189-195.
145. Katzman HE, Glickman MH, Schild AF et al. Multicenter evaluation of the bovine mesenteric vein bioprostheses for hemodialysis access in patients with an earlier failed prosthetic graft. J Am Coll Surg 2005; 201: 223-230.
146. Tahami VB, Hakki H, Reber PU et al. Polytetrafluoroethylene and bovine mesenterial vein grafts for hemodialysis access: a comparative study. J Vasc Access 2007; 8: 17-20.
147. Widmer MK, Aregger F, Stauffer E et al. Intermediate outcome and risk factor assessment of bovine vascular heterografts used as AV-fistulas for hemodialysis access. Eur J Vasc Endovasc Surg 2004; 27: 660-665.
148. Hatzibaloglou A, Velissaris I, Kaitzis D et al. ProCol vascular bioprosthesis for vascular access: midterm results. J Vasc Access 2004; 5: 16-18.
149. Warakaulle DR, Evans AL, Cornall AJ et al. Diagnostic imaging of and radiologic intervention for bovine ureter grafts used as a novel conduit for hemodialysis fistulas. AJR Am J Roentgenol 2007; 188: 641-646.
150. Darby CR, Roy D, Deardon D et al. Depopulated bovine ureteric xenograft for complex haemodialysis vascular access. Eur J Vasc Endovasc Surg 2006; 31: 181-186.
151. Ko PJ, Hsieh HC, Chu JJ et al. Patency rates and complications of Exxcel yarn-wrapped polytetrafluoroethylene grafts versus Gore-tex stretch polytetrafluoroethylene grafts: a prospective study. Surg Today 2004; 34: 409-412.
152. Garcia-Pajares R, Polo JR, Flores A et al. Upper arm polytetrafluoroethylene grafts for dialysis access. Analysis of two different graft sizes: 6 and 6-8 mm. Vasc Endovascular Surg 2003; 37: 335-343.
153. Polo JR, Ligero JM, Diaz-Cartelle J et al. Randomized comparison of 6-mm straight grafts versus 6-8-mm tapered grafts for brachial-axillary dialysis access. J Vasc Surg 2004; 40: 319-324.
154. Cole JS, Watterson JK, O'Reilly MJ. Is there a haemodynamic advantage associated with cuffed arterial anastomoses? J Biomech 2002; 35: 1337-1346.
155. Cole JS, Wijesinghe LD, Watterson JK et al. Computational and experimental simulations of the haemodynamics at cuffed arterial bypass graft anastomoses. Proc Inst Mech Eng [H] 2002; 216: 135-143.
156. Kissin M, Kansal N, Pappas PJ et al. Vein interposition cuffs decrease the intimal hyperplastic response of polytetrafluoroethylene bypass grafts. J Vasc Surg 2000; 31: 69-83.
157. Lin PH, Bush RL, Nguyen L et al. Anastomotic strategies to improve hemodialysis access patency-a review. Vasc Endovascular Surg 2005; 39: 135-142.
158. Berard X, Baste JC, Sassoust G et al. [Retrospective study of the one-year patency of a cuffed polytetrafluoroethylene Venaflo-type graft placed for venous hemodialysis access]. J Mal Vasc 2003; 28: 73-78.
159. Ojha M, Cobbold RS, Johnston KW. Influence of angle on wall shear stress distribution for an end-to-side anastomosis. J Vasc Surg 1994; 19: 1067-1073.
160. Pollman MJ, Hall JL, Mann MJ et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222-227.
161. Morishita R, Higaki J, Tomita N et al. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023-1028.
162. Suzuki J, Isobe M, Morishita R et al. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res 2000; 45: 783-787.
163. Suzuki J, Morishita R, Amano J et al. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000; 7: 1847-1852.
164. Kutryk MJ, Foley DP, van den Brand M et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281-287.
165. Morishita R, Gibbons GH, Horiuchi M et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
166. Ahn JD, Morishita R, Kaneda Y et al. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 2002; 9: 1682-1692.
167. Hashiya N, Aoki M, Tachibana K et al. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model. Biochem Biophys Res Commun 2004; 317: 508-514.
168. Mann MJ, Whittemore AD, Donaldson MC et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
169. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106: 1071-1075.
170. Conte MS, Bandyk DF, Clowes AW et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742-751; discussion 751.
171. Alexander JH, Hafley G, Harrington RA et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-2454.
172. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-543.
173. Hiltunen MO, Laitinen M, Turunen MP et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2000; 102: 2262-2268.
174. Bhardwaj S, Roy H, Heikura T et al. VEGF-A, VEGF-D and VEGF-D( DeltaNDeltaC) induced intimal hyperplasia in carotid arteries. Eur J Clin Investig 2005; 35: 669-676.
175. Walpoth BH, Zammaretti P, Cikirikcioglu M et al. Enhanced intimal thickening of expanded polytetrafluoroethylene grafts coated with fibrin or fibrin-releasing vascular endothelial growth factor in the pig carotid artery interposition model. J Thoracic Cardiovasc Surg 2007; 133: 1163-1170.
176. Komatsu Y, Itoh H, Suga S et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996; 78: 606-614.
177. Ohno N, Itoh H, Ikeda T et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-1626.
178. Rotmans JI, Verhagen HJ, Velema E et al. Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts. Kidney Int 2004; 65: 1897-1905.
179. Luo Z, Akita GY, Date T et al. Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. Circulation 2005; 111: 1679-1684.
180. Rotmans JI, Heyligers JM, Verhagen HJ et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 2005; 112: 12-18.
181. Nugent HM, Sjin RT, White D et al. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg 2007; 46: 548-556.
182. Melhem M, Kelly B, Zhang J et al. Development of a local perivascular paclitaxel delivery system for hemodialysis vascular access dysfunction: polymer preparation and in vitro activity. Blood Purif 2006; 24: 289-298.
183. Kohler TR, Toleikis PM, Gravett DM et al. Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable Vascular Wrap paclitaxel-eluting mesh. J Vasc Surg 2007; 45: 1029-1037; discussion 1037-1028.
184. Kelly B, Melhem M, Zhang J et al. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant 2006; 21: 2425-2431.
185. Gregory CR, Huie P, Billingham ME et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993; 55: 1409-1418.
186. Braun-Dullaeus RC, Mann MJ, Seay U et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001; 21: 1152-1158.
187. Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-2170.
188. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
189. Fajadet J, Morice MC, Bode C et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005; 111: 1040-1044.
190. Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299-1304.
191. Holmes Jr DR, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640.
192. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-9556.
193. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
194. Kaluza GL, Gershlick AH, Park SJ et al. Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials). Am J Cardiol 2004; 94: 199-201.
195. Gershlick A, De Scheerder I, Chevalier B et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109: 487-493.
196. Bullesfeld L, Gerckens U, Muller R et al. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Z Kardiol 2003; 92: 825-832.
197. Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-1947.
198. Lee BH, Nam HY, Kwon T et al. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant 2006; 21: 2432-2438.
199. Himmelfarb J, Couper L. Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int 1997; 52: 1671-1677.
200. Zhuplatov SB, Masaki T, Blumenthal DK et al. Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431-439.
201. Sreedhara R, Himmelfarb J, Lazarus JM et al. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-1483.
202. Singh JP, Rothfuss KJ, Wiernicki TR et al. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol 1994; 23: 665-671.
203. Heidland UE, Heintzen MP, Michel CJ et al. Intracoronary administration of dipyridamole prior to percutaneous transluminal coronary angioplasty provides a protective effect exceeding that of ischemic preconditioning. Coron Artery Dis 2000; 11: 607-613.
204. Kuji T, Masaki T, Goteti K et al. Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int 2006; 69: 2179-2185.
205. Rutherford C, Martin W, Salame M et al. Substantial inhibition of neointimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 1997; 130: 45-51.
206. Davies MG, Owens EL, Mason DP et al. Effect of platelet-derived growth factor receptor-alpha and -beta blockade on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ Res 2000; 86: 779-786.
207. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
208. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
209. Wang WL, Healy ME, Sattler M et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19: 3521-3528.
210. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117-123.
211. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14-S18.
212. Myllarniemi M, Frosen J, Calderon Ramirez LG et al. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther 1999; 13: 159-168.
213. Boucher P, Gotthardt M, Li WP et al. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003; 300: 329-332.
214. Sihvola RK, Tikkanen JM, Krebs R et al. Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. Transplantation 2003; 75: 334-339.
215. Leppanen O, Rutanen J, Hiltunen MO et al. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 2004; 109: 1140-1146.
216. Li L, Blumenthal DK, Masaki T et al. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 2006; 99: 1553-1563.
217. Scott S, O'Sullivan M, Hafizi S et al. Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: implications for brachytherapy and drug treatment for restenosis. Circ Res 2002; 90: 398-404.
218. Wiedermann JG, Marboe C, Amols H et al. Intracoronary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. J Am Coll Cardiol 1994; 23: 1491-1498.
219. Ducasse E, Cosset JM, Eschwege F et al. External beam ionizing radiation for inhibition of myointimal hyperplasia after dilatation and anastomoses: experimental models and results. Ann Vasc Surg 2004; 18: 108-114.
220. Vodovotz Y, Waksman R, Kim WH et al. Effects of intracoronary radiation on thrombosis after balloon overstretch injury in the porcine model. Circulation 1999; 100: 2527-2533.
221. Grise MA, Massullo V, Jani S et al. Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2002; 105: 2737-2740.
222. Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-256.
223. Sun S, Beitler JJ, Ohki T et al. Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula. J Surg Res 2003; 115: 200-208.
224. van Tongeren RB, Levendag PC, Coen VL et al. External beam radiation therapy to prevent anastomotic intimal hyperplasia in prosthetic arteriovenous fistulas: results of a randomized trial. Radiother Oncol 2003; 69: 73-77.
225. Krueger K, Bendel M, Zaehringer M et al. Centered endovascular irradiation to prevent postangioplasty restenosis of arteriovenous fistula in hemodialysis patients; Results of a feasibility study. Cardiovasc Radiat Med 2004; 5: 1-8.